NASDAQ$VRTX

Vertex Pharmaceuticals Incorporated · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

VRTX Q3 2024 — CAD 2.0M revenue

These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of income for the int. Vertex Pharmaceuticals Incorporated reported Q3 2024 results. Net income of CAD 1K. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.

  • Revenue: CAD 2.0M.
  • Net income: CAD 1K.
  • Filed on Form 10-Q (accession 0000875320-24-000223).

Headline financials

Total Revenue

$2.77B

Previous: $2.48B+11.6%
EPS

$4.01

Previous: $4.08-1.7%
Capital Expenditures

-$205M

Previous: -$142M-44.1%
Free Cash Flow

$840M

Previous: $893M-5.9%
Net Income

$1.05B

Previous: $1.04B+1.0%
Operating Income

$1.12B

Previous: $1.04B+7.5%
Gross Profit

$2.38B

Previous: $2.16B+9.9%
Cash & Equivalents

$5.24B

Previous: $11.9B-56.1%
Total Assets

$22.2B

Previous: $21.7B+2.4%
R&D Expense

$875M

Previous: $810M+8.0%
Stock-Based Comp

$185M

Previous: $131M+41.0%

Revenue & EPS history

Vertex · Revenue · Quarterly

$2.77B

Q3 2024+11.6%vs Q3 2023
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

Vertex · $2.27B total across 1 segment · Q3 2023

  • TRIKAFTA/KAFTRIO
    $2.27B+13.1%

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

-0.3%

Avg return

Earnings day

-0.2%

Avg return

5 days after

+1.1%

Avg return

30 days after

46%

32 / 70 earnings

Positive

+6.1%

Q3 2024

Best reaction

-9.4%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.2%-0.1%+3.0%
Q4 2025+5.7%+1.1%+0.9%
Q3 2025-1.1%-3.9%+7.4%
Q2 2025+2.8%-0.1%+5.6%
Q1 2025-9.4%-15.0%-11.3%
Q4 2024-3.1%-2.3%+7.0%
Q3 2024+6.1%+9.7%-1.5%
Q2 2024+0.9%+2.4%-1.9%
Q1 2024+2.3%+5.4%+20.4%
Q4 2023-2.0%-0.4%-3.0%
Q3 2023+0.5%-0.7%-6.0%
Q2 2023-2.4%-1.6%-2.2%
Q1 2023+1.6%+2.2%-5.0%
Q4 2022-3.8%-2.5%-5.9%
Q3 2022+0.9%+1.0%+0.6%
Q2 2022+4.7%+8.7%+2.2%
Q1 2022-7.2%-12.3%-1.6%
Q4 2021+0.5%+7.0%+1.4%
Q3 2021+2.0%+4.0%+10.3%
Q2 2021-0.3%-1.1%-1.1%
Q1 2021+2.2%+0.6%-2.3%
Q4 2020-5.1%-6.0%-9.0%
Q3 2020+0.0%+1.3%+8.8%
Q2 2020-2.4%-1.1%-3.1%
Q1 2020-2.2%+3.0%+12.1%
Q4 2019-2.3%+3.1%-3.6%
Q3 2019-1.2%+0.8%+12.1%
Q2 2019+5.8%+3.6%+6.2%
Q1 2019+0.0%+0.8%-1.3%
Q4 2018-3.0%-3.5%-5.0%
Q3 2018-4.9%-2.2%-7.9%
Q2 2018+0.6%-0.3%+1.1%
Q1 2018+0.6%-1.7%+1.5%
Q4 2017+3.9%-6.8%+2.1%
Q3 2017-4.9%-1.0%-3.0%
Q2 2017-3.6%-6.3%-5.4%
Q1 2017+1.7%+1.8%+3.1%
Q4 2016+3.8%+2.6%+4.7%
Q3 2016-0.0%-1.5%+10.9%
Q2 2016+1.3%+3.4%+2.2%
Q1 2016+3.1%
Q4 2015+0.6%
Q3 2015+4.3%
Q2 2015+5.6%
Q1 2015-1.7%
Q4 2014-7.7%
Q3 2014-1.5%
Q2 2014-3.7%
Q1 2014-2.0%
Q4 2013+3.6%
Q3 2013-7.8%
Q2 2013+1.5%
Q1 2013-1.9%
Q4 2012-2.8%
Q3 2012-6.8%
Q2 2008-1.6%
Q1 2012+2.5%
Q4 2011+2.3%
Q3 2011-0.7%
Q2 2011+4.5%
Q1 2011-1.8%
Q4 2008-1.2%
Q4 2010-1.2%
Q3 2009-0.1%
Q3 2010-0.1%
Q2 2010+5.1%
Q2 2009+5.1%
Q1 2010-0.8%
Q1 2009-0.8%
Q4 2009-0.8%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro